Singapore markets closed
  • Straits Times Index

    3,013.85
    -0.93 (-0.03%)
     
  • Nikkei

    28,864.32
    -65.78 (-0.23%)
     
  • Hang Seng

    29,098.29
    -138.50 (-0.47%)
     
  • FTSE 100

    6,630.52
    -20.36 (-0.31%)
     
  • BTC-USD

    50,754.47
    +1,778.22 (+3.63%)
     
  • CMC Crypto 200

    982.93
    +39.75 (+4.21%)
     
  • S&P 500

    3,841.94
    +73.47 (+1.95%)
     
  • Dow

    31,496.30
    +572.16 (+1.85%)
     
  • Nasdaq

    12,920.15
    +196.68 (+1.55%)
     
  • Gold

    1,698.20
    -2.50 (-0.15%)
     
  • Crude Oil

    66.28
    +2.45 (+3.84%)
     
  • 10-Yr Bond

    1.5540
    +0.0040 (+0.26%)
     
  • FTSE Bursa Malaysia

    1,600.12
    +18.86 (+1.19%)
     
  • Jakarta Composite Index

    6,258.75
    -32.05 (-0.51%)
     
  • PSE Index

    6,881.37
    -1.12 (-0.02%)
     

Geron to Present at the B. Riley Securities Virtual Oncology Investor Conference

·1-min read

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Chairman and Chief Executive Officer, will present a company overview at the B. Riley Securities Virtual Oncology Investor Conference on Wednesday, January 20, at 3:00 p.m. ET.

A live audio webcast of the presentation will be available on Geron’s website, www.geron.com/investors/events. A replay of the webcast will be available on the Company’s website for 30 days.

About Geron

Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. For more information about Geron, visit www.geron.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210114005809/en/

Contacts

Olivia Bloom
Chief Financial Officer
investor@geron.com
media@geron.com